The analysis of the drug–targets based on the topological properties in the human protein–protein interaction network

Analyzing topological properties of drug-target proteins in the biology network is very helpful in understanding the mechanism of drug action. However, comprehensive studies to elaborately characterize the biological network features of drug-target proteins are still lacking. In this paper, we compared the topological properties of drug–targets with those of the non–drug-target sets, by mapping the drug–targets in DrugBank to the human protein interaction network. The results indicate that the topological properties of drug-targets are significantly distinguishable from those of non–drug-targets. Moreover, the potential possibility of drug-target prediction based on these properties is discussed. All proteins in the interaction network were ranked by their topological properties. Among the top 200 proteins, 94 overlapped with drug-targets in DrugBank and some novel predictions were found to be drug–targets in public literatures and other databases. In conclusion, our method explores the topological properties of drug-targets in the human protein interaction network by exploiting the large–scale drug-targets and protein interaction data.

[1]  Duncan J. Watts,et al.  Collective dynamics of ‘small-world’ networks , 1998, Nature.

[2]  B. Schwikowski,et al.  A network of protein–protein interactions in yeast , 2000, Nature Biotechnology.

[3]  Martin Suter,et al.  Small World , 2002 .

[4]  A. Hopkins,et al.  The druggable genome , 2002, Nature Reviews Drug Discovery.

[5]  P. Workman,et al.  HSP90 as a new therapeutic target for cancer therapy: the story unfolds , 2002, Expert opinion on biological therapy.

[6]  Alan F. Scott,et al.  Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders , 2002, Nucleic Acids Res..

[7]  D. Goldberg,et al.  Assessing experimentally derived interactions in a small world , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[8]  Alessandro Vespignani,et al.  Global protein function prediction from protein-protein interaction networks , 2003, Nature Biotechnology.

[9]  H. Hermeking,et al.  The MYC oncogene as a cancer drug target. , 2003, Current cancer drug targets.

[10]  S. Wuchty,et al.  Evolutionary cores of domain co-occurrence networks , 2005, BMC Evolutionary Biology.

[11]  Amy E. Keating,et al.  AVID: An integrative framework for discovering functional relationships among proteins , 2005, BMC Bioinformatics.

[12]  J. Turkson,et al.  STAT proteins as novel targets for cancer drug discovery , 2004, Expert opinion on therapeutic targets.

[13]  A. Barabasi,et al.  Network biology: understanding the cell's functional organization , 2004, Nature Reviews Genetics.

[14]  Lan V. Zhang,et al.  Evidence for dynamically organized modularity in the yeast protein–protein interaction network , 2004, Nature.

[15]  Alain Rakotomamonjy,et al.  Optimizing Area Under Roc Curve with SVMs , 2004, ROCAI.

[16]  Shinichiro Wachi,et al.  Interactome-transcriptome analysis reveals the high centrality of genes differentially expressed in lung cancer tissues , 2005, Bioinform..

[17]  Stefan Wuchty,et al.  Peeling the yeast protein network , 2005, Proteomics.

[18]  Ting Chen,et al.  Further understanding human disease genes by comparing with housekeeping genes and other genes , 2006, BMC Genomics.

[19]  D. Edwards,et al.  Challenges of target/compound data integration from disease to chemistry: a case study of dihydrofolate reductase inhibitors. , 2005, Current drug discovery technologies.

[20]  Paul A. Bates,et al.  Global topological features of cancer proteins in the human interactome , 2006, Bioinform..

[21]  Judith A. Blake,et al.  Beyond the data deluge: Data integration and bio-ontologies , 2006, J. Biomed. Informatics.

[22]  A. Butte,et al.  Creation and implications of a phenome-genome network , 2006, Nature Biotechnology.

[23]  P. Johnston,et al.  BRCA1, a potential predictive biomarker in the treatment of breast cancer. , 2007, The oncologist.

[24]  R. Shamir,et al.  Pathway redundancy and protein essentiality revealed in the Saccharomyces cerevisiae interaction networks , 2007, Molecular systems biology.

[25]  B. Jiang,et al.  Suppression of FHL2 expression induces cell differentiation and inhibits gastric and colon carcinogenesis. , 2007, Gastroenterology.

[26]  A. Barabasi,et al.  Drug—target network , 2007, Nature Biotechnology.

[27]  Zheng Guo,et al.  Globally predicting protein functions based on co-expressed protein-protein interaction networks and ontology taxonomy similarities. , 2007, Gene.

[28]  William Loging,et al.  High-throughput electronic biology: mining information for drug discovery , 2007, Nature Reviews Drug Discovery.

[29]  Xiaowei Xu,et al.  A structural approach for finding functional modules from large biological networks , 2008, BMC Bioinformatics.

[30]  Kara Dolinski,et al.  The BioGRID Interaction Database: 2008 update , 2008, Nucleic Acids Res..

[31]  Ling Yang,et al.  Deducing topology of protein-protein interaction networks from experimentally measured sub-networks , 2008, BMC Bioinformatics.

[32]  Wenyuan Li,et al.  Mapping Genetically Compensatory Pathways from Synthetic Lethal Interactions in Yeast , 2008, PloS one.

[33]  L. Möllgård,et al.  Mutated and non‐mutated TP53 as targets in the treatment of leukaemia , 2008, British journal of haematology.

[34]  David S. Wishart,et al.  DrugBank: a knowledgebase for drugs, drug actions and drug targets , 2007, Nucleic Acids Res..

[35]  L. Rychlewski,et al.  Meta-basic estimates the size of druggable human genome , 2009, Journal of molecular modeling.